Understanding the Latest Tresiba Prescribing Information: What You Need to Know
As a healthcare professional, it is important to stay up-to-date with the latest prescribing information for medications that are commonly used to treat patients. One such medication is Tresiba, a long-acting insulin analog used to treat individuals with diabetes. In this article, we will explore the latest Tresiba prescribing information and what healthcare professionals need to know.
Introduction
Tresiba, also known as insulin degludec, was approved by the US Food and Drug Administration (FDA) in 2015 for the treatment of diabetes in adults. It is a long-acting insulin analog that is designed to provide a steady release of insulin over a period of time, allowing for once-daily dosing.
Body
Dosage and Administration
The recommended starting dose of Tresiba in patients with type 1 or type 2 diabetes is 10 units once daily, which can be adjusted based on individual patient needs. Unlike other long-acting insulin analogs that have specific dosing time requirements, Tresiba can be taken at any time of day as long as there is at least eight hours between doses.
Tresiba FlexTouch Pen
The Tresiba FlexTouch pen is a pre-filled, disposable insulin pen that is available in two different sizes: U-100 and U-200. The U-100 pen contains 100 units of insulin per mL and is available in doses of 100, 200, and 300 units. The U-200 pen contains 200 units of insulin per mL and is available in doses of 200, 300, and 400 units.
Hypoglycemia
Hypoglycemia is a potential side effect of insulin therapy, and patients should be advised to monitor their blood glucose levels closely to avoid this condition. Symptoms of hypoglycemia include shakiness, sweating, confusion, and dizziness. Severe hypoglycemia can lead to seizures and loss of consciousness.
Warnings and Precautions
The prescribing information for Tresiba includes several warnings and precautions that healthcare professionals should be aware of. Some of the most important include the risk of hypoglycemia, hyperglycemia, and ketoacidosis. Additionally, patients with a history of hypoglycemia unawareness may be at an increased risk of severe hypoglycemia.
Conclusion
Tresiba is a long-acting insulin analog that is used to treat individuals with type 1 or type 2 diabetes. The latest prescribing information includes recommendations for dosing and administration, information about the Tresiba FlexTouch pen, and warnings and precautions related to hypoglycemia, hyperglycemia, and ketoacidosis. Healthcare professionals should educate themselves on the latest prescribing information for Tresiba to ensure that their patients receive the highest quality of care.
